Spleen cells from certain unimmunized mouse strains can kill a variety of murine leukemia virus (MuLV ÷) syngeneic or allogeneic tumor cells. This type of 'natural killer' (NK) 1 activity has now been reported in many in vitro systems (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) . Several studies, mainly by Kiessling and his colleagues (9) (10) (11) (12) (13) (14) (15) , have suggested (a) although NK cells are small lymphocytes, they cannot be classified as mature T, B, or monocyte-macrophage cells using standard cell fractionation procedures, (b) NK cells apparently do not bear Fc receptors on their surface and do not mediate antibody-dependent cellular cytotoxicity, (c) the presence of NK activity is controlled in part by genes within the H-2 complex, and (d) there is a correlation between the presence of in vitro NK activity and in vivo resistance to many lymphoid tumors.
Despite this association between NK activity and resistance to tumor growth, it has not been possible to directly test their role in the prevention of tumor growth in vivo or to establish the developmental relationship of NK cells to other lymphoid subpopulations. These tests require the ability to selectively deplete or purify this lymphocyte subclass from a heterogeneous cell population. We describe here the serologic definition of a cell surface component which is selectively expressed on the surface of NK cells active against an MuLV + tumor.
Materials and Methods
Mice. C57BL/6 (B6) mice (Ly phenotype 1.2,2.2,3.2; H-2 b) and BALB/c mice (Ly phenotype 1.2,2.2,3.2; H-2 ~) were obtained from The Jackson Laboratory, Bar Harbor, Maine and the congenic line, B6/Lyl.1, from Dr. E. A. Boyse. NZB, C3H/Bi, CBA/T6, BALB/c, C3H/An, DBA/2, and (BALB/c × B6)FI (H-2 b~) were bred in our animal facilities from breeders supplied by The Jackson Laboratory.
Antisera. The production and use of anti-Lyl.2 (C3H anti-CE thymocyte antiserum), antiLy2.2, and anti-Thyl.2 have been described previously (16) . The Ly antisera were diluted 1:30 and absorbed twice with approximately 120 × 10 e C3H thymus cells/ml to remove autoantibody. AntiThyl.2 was raised in (A/Thyl. 1 × AKR)F1 mice immunized with A-strain leukemic cells (ASLI); this serum had a titer of 1:200 against LN cells and was used at a final dilution of 1:40.
Tumor Cell Line. The tumor used as target cell was the BALB/c (H-2 ~) RLd 1 radiation-induced leukemia obtained from Dr. E. A. Boyse. These cells carry a strong MuLV-associated antigen, X.1, on their cell surface (17) . An in vitro line of RL~I cells was established in our laboratory; the cells were grown in suspension in L15 medium supplemented with 15% tryptose phosphate broth and 15% fetal calf serum and used as targets directly after harvesting. The P815 DBA/2 (H-2 ~) mastocytoma were also used after similar in vitro passage.
Enrichment of Spleen T Cells by Nylon Wool Columns.
Nylon wool columns were used as described previously (18), 80-85% of the effluent cells were Ig-Thyl +, and 1-6% were Ig+Thyl -.
Cytotoxicity Assay. We used the 5~Cr release method of Brunner et al. (19) as modified by
Canty and Wunderlich (20) . Appropriate numbers of attacking cells were mixed with 5 x 104 ~Cr-labeled target cells and incubated 31/2-4 h in an atmosphere of 7% CO~. Cytotoxic activity for each test cell population was determined by the amount of 51Cr released from triplicate cultures of target cells during incubation compared with medium alone (control). Data were calculated by the following formula:
cpm (test population) -cpm (control) % lysis = × 100 cpm maximum release (freeze-thaw)
Standard errors for each triplicate culture were invariably less than 20%. (Table I ). B6 and NZB spleen cells express 'spontaneous' cytotoxicity against the RLd 1 (MuLV +) but not against P815 (MuLV-). Levels of spleen cell cytotoxicity from B6 mice varied from experiment to experiment, ~anging from 15-40% at a 100:1 attacker/target ratio and averaging about 20-30%. NK activity was consistently slightly higher in the NZB (25-40% lysis), a strain known to harbor MuLV.
Results

Spontaneous Cytotoxicity of B6 and NZB Lymphoid Cells to the RLdl Tumor
Various lymphoid organs in the B6 and NZB were analyzed for NK activity. These results are in agreement with previous findings ( (FIG. 2) . To determine whether the NK cells expressed Ly antigens, we treated nylon column-passed spleen cells with Ly sera ÷ C. Treatment with either anti-Ly2.2 or anti-Thyl.2 + C had no affect on NK activity. However, treatment with C3H anti-CE antiserum (anti-Lyl.2) abolished NK activity (Fig. 2 ).
We were surprised by these results. Lyl antigens are thought to be expressed exclusively on T cells, and the NK cell bears no other T-cell markers (e.g., Thyl, Ly2). Therefore, we suspected that the C3H anti-CE antiserum contained antibodies to determinants other than Lyl.2 which are expressed on NK cells. To test this hypothesis, we examined the effects of C3H aCE serum + C upon spleen cells from a congenic pair of B6 mouse strains differing only at the Lyl locus, B6/Lyl. 1, and B6(Lyl.2+). NK activity of spleen cells from both Lyl.1 + and Lyl.2 + congenic B6 strains were equally sensitive to the C3H anti-CE (antiLyl.2) antiserum (Fig. 3) . Hence anti-NK antibody in this serum was not directed at the Lyl.2 antigen. To confirm this point, C3H aCE antisera were absorbed with either B6 or B6/Lyl. 1 spleen cells; both absorptions removed aNK activity (Fig. 4) .
Absorption of C3HaCE Sera to Produce aNK Sera (Fig. 5) . We then absorbed C3H anti-CE antiserum with BALB/c thymus and spleen cells (which are NK-and Lyl.2+). This absorption removed all anti-Lyl.2 activity, as tested by lysis of ~lCr-labeled B6 lymph node cells, but lei~ anti-NK activity intact. This absorbed antiserum, which lysed less than 5% of a whole spleen cell population, therefore reacted with a surface component selectively expressed on NK cells. No loss of NK activity was noted after further absorption of aNK sera (1:30) with equal volumes of brain cells, kidney cells, or fibroblasts (data not shown). Strain Distribution of aRLdl NK Activity and Susceptibility to aNK Antisera (Table II) . Spleen cells from a variety of inbred mouse strains were tested for spontaneous cytolytic activity against RL d 1 target cells. Cells from BALB/c mice and DBA/2 mice did not express significant NK activity. Spleen cells from B6, (BALB/c × B6)F~, and NZB mice produced substantial NK activity; this activity was eliminated after treatment with C3H aCE sera. CBA/T6 and C3H/ Bi spleen cells also expressed significant levels of spontaneous lytic activity; this activity was resistant to treatment with C3H aCE sera + C. (Table III) . To produce sera that would not require absorption with BALB/c cells to eliminate ~Lyl.2 activity, we immunized (C3H × BALB/c)F1 mice with CE spleen cells according to a protocol described previously (16) . This serum did not contain aLyl.2 activity (BALB/c Ly phenotype-Lyl.2, 2.2, 3.2), but retained anti-NK activity. Treatment of B6 spleen cells with this serum + C (a) did not result in detectable lysis above that seen with NMS + C, but (b) virtually eliminated all spontaneous lysis vs. RLJ 1 targets. By contrast the sera had no effect on either B6 T-killer activity or plaque-forming cell activity (or TH activity, data not shown). Thus insertion of the BALB/c NK cells can specifically damage certain types of tumor cells which express MuLV-associated antigens, and this activity has been correlated with in vivo resistance to these tumors (12) . However, it has not yet been possible to identify specific cell-surface markers on NK cells and thus directly test their role in the Our experiments used relatively high attacker:target ratios in order to demonstrate significant NK activity. It is likely that these high ratios were required because NK cells represent less than 5% of the whole spleen cell population, and therefore these studies reflect true NK cell/target ratios of about 1:1-1:5. These considerations indicate that the NK population may exert powerful cytolytic effects on appropriate tumor targets.
Production of Specific aNK Antiserum in (C3H × BALB/c) F~ Mice Immunized to CE Spleen Cells
The C3H anti-CE thymocyte antiserum used in the first part of these experiments was made by injecting CE thymus cell suspensions into C3H mice. Since thymocytes do not express NK activity, it is somewhat surprising that this antiserum contained anti-NK antibody. There are several possible explanations: (a) NK cells may be present in CE thymus, albeit in very small numbers. The repeated injections of large numbers of CE thymocytes (2-5 x 107/wk, 10-15 wk) necessary to produce aLyl.2 antiserum might also be sufficient to raise antibody against NK cells even though our functional assay does not detect significant NK activity. Inasmuch as C3H mice produce anti-NK antibody, which eliminates NK activity from spleen cells of at least two strains, B6 and NZB, but does not affect NK activity of spleen cells from C3H/Bi or CBA/T6 mice, it is likely that the NK alloantigen is expressed either as two or more alleles including 'NK-C3H' and 'NK-B6' or possibly as a single allelic product that is not expressed by C3H or CBA mice. In either case, the present studies demonstrate that at least some mouse strains possess NK cells that can be selectively eliminated by the sera described in this report. The fact that the NK antigen is not expressed on the surface of mature T cells, B cells, kidney cells, or brain cells suggests that it falls into an increasingly useful category of cell-surface differentiation components that are selectively expressed on cells at particular phases of their differentiative history. The contribution of the NK cell-surface component defined in these studies to NK activity has not been extensively investigated, although preliminary experiments indicate the presence of aNK sera does not inhibit NK cellmediated lysis.
The biologic significance of the NK cell is presently incompletely understood. Previous work has shown that (a) there is a correlation between in vitro NK activity and in vivo tumor resistance (12) , and (b) there is a low incidence of RNA tumors in nude (congenital athymic) mice which have high NK activity (13, 14) . For these reasons, it is possible that the NK cell may play a role in immunosurveillance against tumors. Selective removal of NK cells from spleen and bone marrow cells before adoptive transfer to irradiated hosts is now possible and will permit direct testing of this hypothesis.
Summary
We have studied the cell-surface phenotype of natural killer (NK) cells of NZB and B6 mice which react to an MuLV + lymphoid tumor. (a) NK cells do not express Thyl, Ly2, or Ig surface markers. (b) NK cells express an antigen recognized by C3H anti-CE antiserum ('anti-Lyl.2 antiserum'). Inasmuch as NK activity of spleen cells from B6 and B6/Lyl.1 congenic strains were both equally sensitive to C3H anti-CE antiserum, the NK antigen is distinct from Lyl.2. This point was confirmed by the observation that aNK activity was removed by absorption of C3H anti-CE antiserum with spleen cells from either B6 or B6/Lyl.1 congenic strains.
Absorption of C3H aCE serum with BALB/c thymocytes and spleen cells (which are Lyl.2+NK -) removed anti-Lyl.2 activity and left anti-NK activity intact. This absorption step could be circumvented by inserting the BALB/c genotype into the recipient immunized to CE cells (i.e., (C3H x BALB/c)F, aCE spleen cells). This antiserum, provisionally termed 'anti-NK', defines a new subclass of lymphocytes which may play a central role in the immunosurveillance against tumors.
